The global clear aligner industry is undergoing a painful but necessary maturation, marked by high-profile bankruptcies including SmileDirectClub, Klick Aligner, and Haolijia Dental, alongside massive stock devaluations for incumbents like Align Technology. This article argues that these failures are not isolated market events but the explosive eruption of long-concealed structural contradictions: brands lacking core technological substance and clinical delivery capability cannot survive when capital tides recede. The true bottleneck is not manufacturing capacity—3D printers and thermoforming machines can be scaled with capital—but qualified treatment planning design (TPS) capacity. A complete aligner delivery chain comprises clinical data capture, treatment planning design, manufacturing, and clinical monitoring; treatment planning is the technical apex, demanding integration of biomechanical principles, physiological limits, material science, and individual patient conditions. The article introduces the “60-20-20” effectiveness framework, where treatment plan design accounts for 60% of clinical outcomes, and defines four pillars of effective design capacity: professional orthodontic design teams, deep case experience across complexity levels, cloud-based case delivery and production integration, and direct clinical communication with design rationale. It further highlights the 70% global share of traditional fixed orthodontics as a massive conversion opportunity for brands and OEMs with proven moderate and complex case delivery capability. Ultimately, clear aligners are medical devices, not consumer goods; those who invest in medical substance and design capacity will define the next decade.
